Wayritz (rilzabrutinib) and Myqorzo (aficamten) were on the list of drugs that were expected to be approved by the FDA in the second half of 2025. The drug regulator approved a total of 46 new drugs ...

At Cigna Healthcare, 2026 will be a year defined by making healthcare simpler, more affordable and more intuitive for the ...

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

Liraglutide, a generic of Saxenda, is approved to treat adults and adolescents who are obese or overweight. If approved, ...

In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising ...

Researchers reveal ELI-002 2P cancer vaccine shows promise in boosting immune responses for colorectal and pancreatic cancer ...

Self-collected samples to test for cervical cancer are a step in the right direction when it comes to addressing healthcare ...

The FDA warned against unapproved sunscreen forms, while Australian tests exposed inaccurate SPF claims, causing consumer ...

Tylenol and autism, the Inflation Reduction Act, the One Big Beautiful Bill, Most Favored Nation pricing and direct drug ...

Transparency, prior authorization, PBM reform and PBM offered genomics testing are some the trends Formulary Watched tracked ...